Arrowhead Pharmaceuticals, Inc. (ARWR) scores 64 out of 100 on boothcheck's 11-model valuation framework. Verdict: Fair The estimated fair value is 49.74, representing a 21% premium to fair value. Quantitative score: 64/100. Qualitative score: 70/100.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.